Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 4/2018

01-12-2018 | short review

The microbiome of the prostate

Authors: Christa Strasser, MD, Sebastian Graf, Volkmar Tauber, Steffen Krause

Published in: memo - Magazine of European Medical Oncology | Issue 4/2018

Login to get access

Summary

The intestinal microbiome plays a significant role in modulation of the immune system and carcinogenesis. An increasing number of studies are now investigating the microbiome and the effect of dysbiosis on urological diseases.
Studies investigating the bacterial composition of urine and prostate tissue as well as fecal bacteria clearly demonstrated an association between the alteration in bacterial composition and prostate cancer. Furthermore, patients with and without prostate cancer seem to have a distinct cluster of bacteria that alter metabolic pathways including androgen and testosterone synthesis.
Apart from the interaction of the immune system and microbial composition, there is compelling evidence that the microbiome is involved in modulation of treatment efficacy. Therefore, a dysbiosis of the intestinal microbiome compromises the efficacy of PD-1 immunotherapy. Furthermore, androgen deprivation therapies (ADT), as well as androgen receptor targeting agents (ARTA) including bicalutamide, enzalutamide, and abiraterone acetate, seem to have an influence on the intestinal microbiome.
Microbiome research is a virgin soil in science and will provide further insights into a new area that affects the development of cancer. Based on this information, new therapeutic strategies and prevention options could be found in the future.
Literature
1.
Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018;111:122–8.CrossRefPubMed
2.
Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113(6):986–92.CrossRefPubMed
3.
Ruiz L, Delgado S, Ruas-Madiedo P, Sánchez B, Margolles A. Bifidobacteria and their molecular communication with the immune system. Front Microbiol. 2017;8:2345.CrossRefPubMedPubMedCentral
4.
Bull MJ, Plummer NT. Part 1: the human gut Microbiome in health and disease. Integr Med (Encinitas). 2014;13(6):17–22.
5.
Shrestha E, White JR, Yu S‑H, Kulac I, Ertunc O, De Marzo AM, et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 2018;199(1):161–71.CrossRefPubMed
6.
Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, Lucianò R, Ceresola ER, et al. The microbiome of the prostate tumor microenvironment. Eur Urol. 2017;72(4):625–31.CrossRefPubMed
7.
8.
Wu X, Wu Y, He L, Wu L, Wang X, Liu Z. Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer. J Cancer. 2018;9(14):2510–7.CrossRefPubMedPubMedCentral
9.
10.
Markle JGM, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339(6123):1084–8.CrossRefPubMed
11.
Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 2015;39(4):509–21.CrossRefPubMed
12.
Ridlon JM, Ikegawa S, Alves JMP, Zhou B, Kobayashi A, Iida T, et al. Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. J Lipid Res. 2013;54(9):2437–49.CrossRefPubMedPubMedCentral
13.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.CrossRef
14.
Metadata
Title
The microbiome of the prostate
Authors
Christa Strasser, MD
Sebastian Graf
Volkmar Tauber
Steffen Krause
Publication date
01-12-2018
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 4/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0451-8

Other articles of this Issue 4/2018

memo - Magazine of European Medical Oncology 4/2018 Go to the issue

editorial

Personalized prostate cancer diagnosis and treatment—are we ready?

short review

The impact of surgery in oligometastatic prostate cancer

short review

ASCO 2018 highlights: metastatic breast cancer

short review

Cure in metastatic disease: how to manage and who is the right patient in colorectal cancer?

short review

ASCO 2018: highlights of urothelial cancer and prostate cancer

short review

Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits